CD19 and hepatocellular carcinoma: In the diabetic groups, the highest level of CD19+CD24intCD38int B cells was seen in the CHC-HCC patients (52.5 ± 3), in comparison with the controls (p = 0.007) and the CHC-N group (p = 0.002).